1-2 of 2
Yacine Salhi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma

Hanlon Sia, Peter T. Tan, Joshua Richter, Phoebe Joy Ho, Tara Cochrane, Hang Quach, Binod Dhakal, Igor Proscurshim, Tony Jiang, Emaryn Mancino, Yacine Salhi, Sammicheli Stefano, Girish Gudi, Andrew Garton, Eric J. Feldman, Andrew Spencer
Journal: Blood
Blood (2022) 140 (Supplement 1): 10182–10184.
https://doi.org/10.1182/blood-2022-157585
Published: 2022
Journal Articles

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Sanjay R Mohan, Cristiana Costa Chase, Jesus G Berdeja, Lionel Karlin, Karim Belhadj, Aurore Perrot, Philippe Moreau, Cyrille Touzeau, Thomas Chalopin, Alexander M Lesokhin, Carol Ann Huff, David H. Vesole, Joshua Richter, Jeffrey V. Matous, Igor Proscurshim, Eileen Wolff, Girish Gudi, Andrew Garton, Vinu Menon, Sunitha Gn, Yacine Salhi, Eric J. Feldman, Mohamad Mohty
Journal: Blood
Blood (2022) 140 (Supplement 1): 7264–7266.
https://doi.org/10.1182/blood-2022-157525
Published: 2022